TY - JOUR
T1 - Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA
T2 - Implications for diagnostic prostatic pathology
AU - Varma, Murali
AU - Morgan, Meleri
AU - Jasani, Bharat
AU - Tamboli, Pheroze
AU - Amin, Mahul B.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002/8
Y1 - 2002/8
N2 - Prostate-specific antigen (PSA) production by nonprostatic tissues has been reported, casting doubts on its specificity. The immunohistochemical relative specificity and sensitivity of PSA expression using monoclonal and polyclonal anti-PSA was analyzed on 60 prostate carcinomas, 40 normal seminal vesicles, and 310 nonprostatic tumors. All nonprostatic tumors proved negative with both antibodies. However, 13 (32%) seminal vesicles showed immunoreactivity with polyclonal anti-PSA, but none showed immunoreactivity with the monoclonal antibody. The sensitivity of the 2 antibodies for prostate cancer varied with tumor grade. In Gleason pattern 3, both antibodies showed diffuse immunostaining in all cases. In Gleason pattern 5, polyclonal anti-PSA showed diffuse (>95%) tumor cell positivity in 18 cases (90%), while with the monoclonal antibody, 7 cases (35%) showed only focal (<10%) tumor cell immunoreactivity. Thus, monoclonal anti-PSA seems to be useful in small gland proliferations in which the differential diagnosis includes seminal vesicle, while for poorly differentiated neoplasms, polyclonal anti-PSA is considered superior. Sections of high-grade prostate cancer should be included as positive controls for PSA immunostaining.
AB - Prostate-specific antigen (PSA) production by nonprostatic tissues has been reported, casting doubts on its specificity. The immunohistochemical relative specificity and sensitivity of PSA expression using monoclonal and polyclonal anti-PSA was analyzed on 60 prostate carcinomas, 40 normal seminal vesicles, and 310 nonprostatic tumors. All nonprostatic tumors proved negative with both antibodies. However, 13 (32%) seminal vesicles showed immunoreactivity with polyclonal anti-PSA, but none showed immunoreactivity with the monoclonal antibody. The sensitivity of the 2 antibodies for prostate cancer varied with tumor grade. In Gleason pattern 3, both antibodies showed diffuse immunostaining in all cases. In Gleason pattern 5, polyclonal anti-PSA showed diffuse (>95%) tumor cell positivity in 18 cases (90%), while with the monoclonal antibody, 7 cases (35%) showed only focal (<10%) tumor cell immunoreactivity. Thus, monoclonal anti-PSA seems to be useful in small gland proliferations in which the differential diagnosis includes seminal vesicle, while for poorly differentiated neoplasms, polyclonal anti-PSA is considered superior. Sections of high-grade prostate cancer should be included as positive controls for PSA immunostaining.
KW - Immunohistochemistry
KW - Prostate
KW - Prostate-specific antigen
KW - Seminal vesicles
KW - Sensitivity
KW - Specificity
UR - http://www.scopus.com/inward/record.url?scp=0036675040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036675040&partnerID=8YFLogxK
U2 - 10.1309/BGWQ-P26T-7TR6-VGT3
DO - 10.1309/BGWQ-P26T-7TR6-VGT3
M3 - Article
C2 - 12162678
AN - SCOPUS:0036675040
VL - 118
SP - 202
EP - 207
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
SN - 0002-9173
IS - 2
ER -